Anixa CEO buys 5,000 shares of stock at $2.76

Anixa’s CEO and director Amit Kumar increased his direct common stock holdings through a 5,000‑share open‑market purchase.

Rhea-AI Filing Summary

Anixa Biosciences Inc (ANIX) director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock on September 10, 2026 at $2.76 per share in an open-market or private transaction. Following this purchase, he directly owns 662,000 shares of Anixa common stock. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider KUMAR AMIT

Role Chief Executive Officer

Bought 5,000 shs ($14K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$2.76	$14K

Holdings After Transaction: Common Stock — 662,000 shares (Direct)

Key Figures

Shares purchased: 5,000 shares Purchase price per share: $2.76 per share Post-transaction holdings: 662,000 shares +1 more

4 metrics

Shares purchased 5,000 shares Common stock bought by Amit Kumar on September 10, 2026

Purchase price per share $2.76 per share Price paid for ANIX common stock in the reported transaction

Post-transaction holdings 662,000 shares Direct common stock ownership by Amit Kumar after the purchase

Net shares bought 5,000 shares Net buy volume across all transactions reported in this Form 4

Key Terms

Purchase in open market or private transaction, Rule 10b5-1 trading plan, Direct ownership

3 terms

Purchase in open market or private transaction market

"Characterized as a purchase in open market or private transaction"

Rule 10b5-1 trading plan regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Direct ownership financial

"Following this purchase, he directly owns 662,000 shares"

FAQ

What insider transaction did ANIX report for Amit Kumar?

Amit Kumar purchased 5,000 shares of Anixa common stock on September 10, 2026 at $2.76 per share in an open-market or private transaction, increasing his direct holdings to 662,000 shares.

What is Amit Kumar’s total ANIX share ownership after this transaction?

After the reported purchase, Amit Kumar directly owns 662,000 shares of Anixa Biosciences Inc common stock, as stated in the filing’s post-transaction holdings field.

At what price did the ANIX insider buy shares?

The insider, Amit Kumar, bought 5,000 ANIX shares at $2.76 per share on September 10, 2026, characterized as a purchase in an open-market or private transaction.

Was the ANIX insider trade made under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported for this 5,000-share purchase by Amit Kumar.

Is Amit Kumar a director or officer of Anixa Biosciences Inc (ANIX)?

Yes. Amit Kumar is identified as both a director and the Chief Executive Officer of Anixa Biosciences Inc in connection with this insider purchase of 5,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 08:01 AM Accepted by SEC EDGAR 09/11/2026 - 08:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUMAR AMIT

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		P		5,000	A	$2.76	662,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amit Kumar	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)